Vaccine Adjuvants Market Trends, Sales, Supply, Demand and Analysis by Forecast to 2035
Several Vaccine developers have demonstrated a preference of incorporating vaccine adjuvants owing to various advantages offered by such agents, including the increased efficacy of existing vaccines.
The vaccine adjuvants market is estimated to be worth $4.3 billion in 2022 and is expected to grow at compounded annual growth rate (CAGR) of 2.7% during the forecast period.
Vaccines have enabled the prevention of more than 37 million deaths due to various disease indications, such as cholera, diphtheria, influenza, tetanus, whooping cough and measles, between 2000 to 2019. Given the rate at which the global population is growing and taking into consideration the prevalent (such as the COVID-19 pandemic) and anticipated future trends, the demand for vaccines is likely to increase significantly. According to experts, the global vaccines market is anticipated to generate revenues worth USD 100 billion by 2025. In this regard, significant strides have been made to develop safe and effective, next generation vaccine candidates, such as sub-unit vaccines, recombinant vaccines, conjugate vaccines and DNA vaccines. However, such vaccines employ purified non-living vaccine antigens (unlike their counterparts, live attenuated and inactivated vaccines) and are, most often, less immunogenic and require an additional aid to increase their immunogenicity against the target antigens. As a result, a variety of vaccine adjuvants (substances with the innate potential to augment an immune response), such as AS04 (Cervarix®), MF59 (Fluad®), AS01B (Shingrix®) and CpG 1018 (Heplisav-B®), have been discovered and are now available for the development of more effective and versatile vaccine formulations.
Presently, an increasing number of vaccines under development are incorporating vaccine adjuvants owing to various advantages offered by such agents, including improved adaptive response to a vaccine, guiding the type of adaptive response to produce the most effective forms of immunity for each specific pathogen and facilitation of the use of smaller doses of antigen. Further, majority of the adjuvants used in human vaccines enhance humoral immunity; however, several novel adjuvants in clinical or preclinical development are focused on enhancing specific types of T-cell responses to generate multifaceted immune responses required for complex indications, such as malaria and HIV-AIDS. Currently, more than 70 companies and academic / research institutes are engaged in the development of various types of vaccine adjuvants. It is worth highlighting that capital investments worth over USD 5.5 billion have been made by various private and public sector investors during the last five years to fund the product development activity in this domain. In addition, there have been several recently reported instances of collaborations between industry / academic stakeholders to advance the development of various vaccine adjuvants. Driven by the increasing demand for safe and effective vaccines, ongoing pace of innovation in this field and financial support from the investors, the vaccine adjuvants market is likely to witness substantial growth in the mid to long-term.
Vaccine Adjuvant Developers – Current Market Landscape The continuously growing pharmaceutical industry and demand for safe and effective vaccines amidst the pandemic has led to an increase in the development of vaccine adjuvants. As a result, vaccine developers are trying to incorporate vaccine adjuvants with their respective product to increase its efficacy and efficiency. Moreover, vaccine adjuvants play an important role in improving adaptive response to a vaccine, guiding the type of adaptive response to produce the most effective forms of immunity for each specific pathogen and facilitation of the use of smaller doses of antigen. During our research, we identified more than 70 companies that are actively involved in developing close to 110 vaccine adjuvants.
Thank you for reading our report. Kindly get in touch with us to know more about the report or to receive a customized copy of it. Our team will ensure the report is tailored according to your needs.
To view more details on this report, click on the link https://www.rootsanalysis.com/reports/metabolomics-services-market.html
About Roots Analysis Roots Analysis is a global leader in the pharma / biotech market research. Having worked with over 750 clients worldwide, including Fortune 500 companies, start-ups, academia, venture capitalists and strategic investors for more than a decade, we offer a highly analytical / data-driven perspective to a network of over 450,000 senior industry stakeholders looking for credible market insights. We specialise in analysing areas which have lacked quality research so far or require more focused understanding within the broader industry. All our reports are structured in a way to enable the reader develop a thorough perspective on the given subject. Apart from writing reports on identified areas, we also provide bespoke research / consulting services dedicated to serve our clients in the best possible way. The research efforts are driven by a global team. The leadership team brings a wealth of experience within the sector. Their collective experience in pharmaceutical / affiliated domains allows us to tackle various areas of research in a structured way. We also regularly leverage our global network of experts who hold senior leadership positions in reputed firms and organisations worldwide.
Contact Details Roots Analysis Gaurav Chaudhary +1 (415) 800 3415 +44 (122) 391 1091 [email protected] Website: https://www.rootsanalysis.com/